<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00146029</url>
  </required_header>
  <id_info>
    <org_study_id>UMCC 3-27</org_study_id>
    <nct_id>NCT00146029</nct_id>
  </id_info>
  <brief_title>Companion Pharmacogenetic Study to UMCC 9900/9901</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Rogel Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan Rogel Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose is to examine the original breast tumor material to see how much of a
      metabolizing enzyme (CYP3A4) is present in tumor material. The researchers want to see if
      this is in any way associated with how the patient responded to docetaxel. They also want to
      examine the genes in the tumor that are responsible for the production of CYP metabolizing
      enzymes, to see if they are normal or if they have polymorphisms, or change compared to
      'normal' CYP metabolizing enzymes.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <condition>Metastatic Breast Cancer</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who participated on UMCC 9900/9901

          -  Living patients must give written informed consent

        Exclusion Criteria:

          -  No tumor block tissue available
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne F. Schott, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Rogel Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <last_update_submitted>March 24, 2008</last_update_submitted>
  <last_update_submitted_qc>March 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2008</last_update_posted>
  <keyword>Patients who participated in UMCC 9900/9901 (Phase II Studies of Tailored-Dose Docetaxel in Metastatic Breast Cancer)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

